MX2020013270A - Oligonucleotidos que comprenden enlace internucleosidico de fosforotritioato. - Google Patents

Oligonucleotidos que comprenden enlace internucleosidico de fosforotritioato.

Info

Publication number
MX2020013270A
MX2020013270A MX2020013270A MX2020013270A MX2020013270A MX 2020013270 A MX2020013270 A MX 2020013270A MX 2020013270 A MX2020013270 A MX 2020013270A MX 2020013270 A MX2020013270 A MX 2020013270A MX 2020013270 A MX2020013270 A MX 2020013270A
Authority
MX
Mexico
Prior art keywords
oligonucleotides
internucleoside linkage
phosphorotrithioate
phosphorotrithioate internucleoside
oligonucleotide
Prior art date
Application number
MX2020013270A
Other languages
English (en)
Inventor
Konrad Bleicher
Adrian Schaeublin
Martina Brigitte Duschmalé
Troels Koch
Meiling Li
Joerg Jakob Andreas Duschmalé
Erich Koller
Original Assignee
Roche Innovation Ct Copenhagen As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Innovation Ct Copenhagen As filed Critical Roche Innovation Ct Copenhagen As
Publication of MX2020013270A publication Critical patent/MX2020013270A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/02—Phosphorylation
    • C07H1/04—Introducing polyphosphoric acid radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA

Abstract

La presente invención se refiere a un oligonucleótido que comprende al menos un enlace internucleosídico de fosforotritioato de la Fórmula (I) como se define en la descripción y en la reivindicación. El oligonucleótido de la invención se puede usar como un medicamento.
MX2020013270A 2018-07-31 2019-07-29 Oligonucleotidos que comprenden enlace internucleosidico de fosforotritioato. MX2020013270A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18186677 2018-07-31
PCT/EP2019/070331 WO2020025527A1 (en) 2018-07-31 2019-07-29 Oligonucleotides comprising a phosphorotrithioate internucleoside linkage

Publications (1)

Publication Number Publication Date
MX2020013270A true MX2020013270A (es) 2021-02-18

Family

ID=63113391

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020013270A MX2020013270A (es) 2018-07-31 2019-07-29 Oligonucleotidos que comprenden enlace internucleosidico de fosforotritioato.

Country Status (12)

Country Link
US (1) US20210221837A1 (es)
EP (1) EP3830101A1 (es)
JP (1) JP2021532075A (es)
KR (1) KR20210041537A (es)
CN (1) CN112236439A (es)
AU (1) AU2019313443A1 (es)
BR (1) BR112020025272A2 (es)
CA (1) CA3098267A1 (es)
IL (1) IL280254A (es)
MX (1) MX2020013270A (es)
TW (1) TW202019944A (es)
WO (1) WO2020025527A1 (es)

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE239484T1 (de) 1991-10-24 2003-05-15 Isis Pharmaceuticals Inc Derivatisierte oligonukleotide mit verbessertem aufnahmevermögen
US5864031A (en) * 1994-07-29 1999-01-26 Amgen Inc. Process for preparing 5-dithio-modified oligonucleotides
US6825174B2 (en) * 1995-06-07 2004-11-30 East Carolina University Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
CA2303299C (en) 1997-09-12 2016-02-23 Exiqon A/S Oligonucleotide analogues
NZ513402A (en) 1999-02-12 2003-06-30 Sankyo Co Novel nucleosides and oligonucleotide analogues
CA2372085C (en) 1999-05-04 2009-10-27 Exiqon A/S L-ribo-lna analogues
US6617442B1 (en) 1999-09-30 2003-09-09 Isis Pharmaceuticals, Inc. Human Rnase H1 and oligonucleotide compositions thereof
US7687617B2 (en) 2002-11-18 2010-03-30 Santaris Pharma A/S Oligonucleotides with alternating segments of locked and non-locked nucleotides
WO2006116458A2 (en) * 2005-04-26 2006-11-02 Coley Pharmaceutical Gmbh Modified oligoribonucleotide analogs with enhances immunostimulatory activity
JP5342881B2 (ja) 2006-01-27 2013-11-13 アイシス ファーマシューティカルズ， インコーポレーテッド ６−修飾された二環式核酸類似体
KR101407707B1 (ko) 2006-04-03 2014-06-19 산타리스 팔마 에이/에스 Ａｎｔｉ-ｍｉｒｎａ 안티센스 올리고뉴클레오타이드를 함유하는 약학적 조성물
DK2015758T3 (da) 2006-05-05 2014-06-23 Isis Pharmaceuticals Inc Forbindelser og fremgangsmåder til modulering af ekspression af apob
US7547684B2 (en) 2006-05-11 2009-06-16 Isis Pharmaceuticals, Inc. 5′-modified bicyclic nucleic acid analogs
US7666854B2 (en) 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
ES2377327T5 (es) 2006-10-18 2020-04-28 Ionis Pharmaceuticals Inc Compuestos antisentido
DK2149605T3 (da) 2007-03-22 2013-09-30 Santaris Pharma As Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
US8278425B2 (en) 2007-05-30 2012-10-02 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
WO2008154401A2 (en) 2007-06-08 2008-12-18 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
AU2008272918B2 (en) 2007-07-05 2012-09-13 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
WO2009043354A2 (en) 2007-10-04 2009-04-09 Santaris Pharma A/S Combination treatment for the treatment of hepatitis c virus infection
US8546556B2 (en) 2007-11-21 2013-10-01 Isis Pharmaceuticals, Inc Carbocyclic alpha-L-bicyclic nucleic acid analogs
DK2356129T3 (da) 2008-09-24 2013-05-13 Isis Pharmaceuticals Inc Substituerede alpha-L-bicykliske nukleosider
WO2011017521A2 (en) 2009-08-06 2011-02-10 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
US8846637B2 (en) 2010-06-08 2014-09-30 Isis Pharmaceuticals, Inc. Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
EP3067421B1 (en) 2011-02-08 2018-10-10 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
DK2742135T4 (da) 2011-08-11 2020-07-13 Ionis Pharmaceuticals Inc Bindingsmodificerede gapped oligomeriske forbindelser og anvendelser deraf
US10023861B2 (en) 2011-08-29 2018-07-17 Ionis Pharmaceuticals, Inc. Oligomer-conjugate complexes and their use
EP2753631A1 (en) 2011-09-07 2014-07-16 Marina Biotech, Inc. Synthesis and uses of nucleic acid compounds with conformationally restricted monomers
EP2850092B1 (en) 2012-04-09 2017-03-01 Ionis Pharmaceuticals, Inc. Tricyclic nucleic acid analogs
US10077443B2 (en) * 2012-11-15 2018-09-18 Roche Innovation Center Copenhagen A/S Oligonucleotide conjugates
CA2921514C (en) 2013-05-01 2023-10-24 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating apolipoprotein c-iii expression
CN112263682A (zh) 2013-06-27 2021-01-26 罗氏创新中心哥本哈根有限公司 靶向pcsk9的反义寡聚体和缀合物
KR102287532B1 (ko) 2014-01-30 2021-08-11 에프. 호프만-라 로슈 아게 생분해성 컨쥬게이트를 갖는 폴리 올리고머 화합물
EP3253871A1 (en) 2015-02-04 2017-12-13 Bristol-Myers Squibb Company Lna oligonucleotides with alternating flanks
EP3394258B1 (en) 2015-10-22 2021-09-22 Roche Innovation Center Copenhagen A/S In vitro toxicity screening assay
JP2019522026A (ja) * 2016-07-27 2019-08-08 ロシュ イノベーション センター コペンハーゲン エーエス 非キラル３’−ｓ−または５’−ｓ−ホスホロチオエートヌクレオシド間結合を含むオリゴヌクレオチドの合成

Also Published As

Publication number Publication date
WO2020025527A1 (en) 2020-02-06
BR112020025272A2 (pt) 2021-03-09
CN112236439A (zh) 2021-01-15
IL280254A (en) 2021-03-01
AU2019313443A1 (en) 2020-11-26
TW202019944A (zh) 2020-06-01
EP3830101A1 (en) 2021-06-09
CA3098267A1 (en) 2020-02-06
JP2021532075A (ja) 2021-11-25
US20210221837A1 (en) 2021-07-22
KR20210041537A (ko) 2021-04-15

Similar Documents

Publication Publication Date Title
AU2024201770A1 (en) Complement component iRNA compositions and methods of use thereof
MX2020005754A (es) Oligonucleotidos gapmeros que comprenden un enlace internucleosido fosforoditioato.
MX2019008380A (es) Composiciones de arni contra el componente c5 del complemento y metodos para su uso.
SG10201809290SA (en) Compositions and Methods to Treating Hemoglobinopathies
PH12015502493A1 (en) Compositions and methods for modulating hbv and ttr expression
WO2015106128A3 (en) Rnai agents modified at the 4'-c-position
NZ720478A (en) Autotaxin inhibitor compounds
PH12018500379A1 (en) Biopharmaceutical compositions
EP3878445A3 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
PH12019501722A1 (en) Compositions and methods for promoting hair growth with mpc1 inhibitors
MX2020011817A (es) Metodos para tratar el linfoma.
MX2019010101A (es) Composiciones y metodos para promover el crecimiento del cabello con inhibidores de mpc1.
EA201791986A1 (ru) Олигонуклеотиды, соответствующие экзону 73 гена col7a1, для терапии буллезного эпидермолиза
ES2673028T3 (es) Reducción selectiva de la actividad perjudicial de genes que contienen repeticiones de trinucleótidos prolongadas
NZ741841A (en) Antisense oligonucleotides for use in treating alzheimer’s disease
MX2021001019A (es) Oligonucleotidos que comprenden enlace internucleosidico de fosforotritioato.
BR112015016391A2 (pt) carboxamidas i baseadas em pirazolil como inibidoras do canal crac
BR112015016394A2 (pt) carboxamidas ii baseadas em pirazolil como inibidoras do canal crac
MX2020006430A (es) Oligonucleotidos que comprenden un enlace internucleosidico de fosforoditioato.
MX2020013270A (es) Oligonucleotidos que comprenden enlace internucleosidico de fosforotritioato.
BR112014013374A2 (pt) formulações de acamprosato, métodos de usar o mesmo, e as combinações que compõem o mesmo
MX2017013879A (es) Composiciones que comprenden anakinra.
WO2016030899A8 (en) Methods of treating amyotrophic lateral scleroses
UA117563C2 (uk) Композиція для лікування або профілактики хвороби, асоційованої з інфекцією впл
MX2022007663A (es) Tieniloxazolonas y analogos.